HC Wainwright keeps USD 25 target for Voyager Therapeutics stock

Published on 10/20/2026 at 13:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Voyager reported USD 3.17 million revenue in the second quarter, down from USD 5.20 million. Voyager Therapeutics stock costs EUR 1.83 on October 20, 2026.

Analyst target and reporting date

HC Wainwright maintained a USD 25.00 price target on October 8, 2026.
Second-quarter revenue was USD 3.17 million, down from USD 5.20 million in the prior-year quarter.
Voyager Therapeutics stock trades at EUR 1.83 at 1:37 p.m. CEST at Lang & Schwarz on October 20, 2026.
Voyager is expected to report its next quarterly results on November 10, 2026.

VYGR, US92915B1061, Illustration mit AI erstellt.

Voyager Therapeutics (US92915B1061) stock is priced at EUR 1.83 at Lang & Schwarz on October 20, 2026 at 1:37 p.m. CEST. The latest analyst action came from Yahoo Finance, which reported on October 8, 2026 that HC Wainwright maintained its Buy rating and USD 25.00 target.

Analyst target stays at USD 25

The unchanged target leaves a wide gap between the analyst view and the current euro quotation, but the target is denominated in USD and is not combined with the Lang & Schwarz price. Voyager's operating profile remains that of a clinical-stage biotechnology company developing gene therapies for neurological diseases.

Voyager Therapeutics identifies programs targeting Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis and Friedreich ataxia. Its listed partners include Alexion, AstraZeneca Rare Disease, Novartis Pharma and Neurocrine Biosciences.

What did the second quarter show?

According to Markets Insider, Voyager reported USD 3.17 million of revenue for the quarter ended June 30, 2026, versus USD 5.20 million in the prior-year quarter. GAAP net loss narrowed to USD 24.47 million from USD 33.38 million, while the quarterly loss was USD 0.40 per share.

Three dated company developments

On July 13, 2026, Voyager said a single intravenous dose of VY1706 was well tolerated in a six-month GLP toxicology study, with an Alzheimer disease trial expected in the second half of 2026. On August 6, 2026, the company reported second-quarter revenue of USD 3.17 million and a GAAP net loss of USD 24.47 million. On October 8, 2026, HC Wainwright maintained its Buy rating and USD 25.00 target, as reported by Yahoo Finance.

When are the next results due?

Tickeron lists November 10, 2026 as Voyager's expected next earnings date. The upcoming report will give investors a fresh read on cash use after cash and cash equivalents stood at USD 35.77 million on June 30, 2026.

Pipeline progress remains central

Voyager's valuation continues to depend heavily on clinical progress because second-quarter revenue fell 39.13 percent year over year while the company remained loss-making. Its pipeline spans neurological conditions, and the investor-relations page lists the second-quarter report dated August 6, 2026 among the company's latest releases.

Stock quote and reporting date

The Nasdaq-listed stock was trading at EUR 1.83 at Lang & Schwarz on October 20, 2026 at 1:37 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Voyager Therapeutics stock.